Celcuity submits sNDA for REVTORPYK in breast cancer

Celcuity submitted a supplemental New Drug Application to the FDA for REVTORPYK targeting breast cancer patients with a PIK3CA mutation. Market relevance: If approved, it could become the first therapy to inhibit all class I PI3K isoforms in advanced breast cancer.